AbbVie is a research-based biopharmaceutical company focused on developing and marketing innovative therapies in several key therapeutic areas including immunology, oncology, neuroscience, and ophthalmology.
**Financial Instrument Update: AbbVie?s XS1520899532 Bond Reaches Maturity and Repayment** This report details the successful maturity and subsequent repayment of a specific bond issued by AbbVie, the global biopharmaceutical company. AbbVie Inc., established in 2013 as a spin-off from Abbott Laboratories, is a leading research-based pharmaceutical firm dedicated to developing and commercializing advanced therapies across diverse therapeutic areas including immunology, oncology, neuroscience, and virology, contributing significantly to global healthcare innovation. The bond, identified by ISIN code XS1520899532, was originally issued from the United States with a principal currency denomination of EUR. It carried an annual interest rate of 1.375% and was part of a total issuance valued at EUR 1,450,000,000, with a minimum purchase size set at EUR 100,000 for investors who received annual interest payments. The security?s maturity date was set for May 17, 2024, and it has been confirmed that this obligation has now reached its full maturity and been repaid at 100% of its face value, concluding its lifecycle as a successfully managed financial instrument.
|
Français
Italiano
United States
XS1520899532 ( in EUR )
